Autolus Therapeutics PLC
NASDAQ:AUTL
Autolus Therapeutics PLC
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.
Net Sales: AUCATZYL achieved $21.1 million in net product revenue for Q3 2025, up slightly from $20.9 million in Q2.
Market Leadership: Autolus gained market leadership in relapsed/refractory B-ALL in its first 9 months on the US market, with broad access and reliable delivery.
Deferred Revenue: Deferred revenue at quarter-end was $7.6 million, a significant increase from $2.1 million in Q2, indicating products delivered but not yet infused.
Cost of Sales & Margins: Cost of sales was $28.6 million, with management expecting improvements as volumes rise and operational efficiency increases.
Pipeline Progress: Multiple expansion studies underway, including pivotal trials in pediatric ALL and lupus nephritis, and an exploratory study in progressive multiple sclerosis.
Cash Position: Ended Q3 with $367.4 million in cash and equivalents, expected to fund ongoing launches and pivotal trials.
Operational Stability: Manufacturing success rate above 90%, and coverage for over 90% of US covered lives.
